Cytokine blockade in sepsis--Are two better than one?
Hotchkiss
R S
RS
Karl
I E
IE
D000818:Animals; D015703:Antigens, CD / Q000627:therapeutic use*; D003422:Critical Care / Q000379:methods; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D007249:Inflammation; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1 / Q000037:antagonists & inhibitors*; D051379:Mice; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D047888:Receptors, Tumor Necrosis Factor, Type I; D018805:Sepsis / Q000188:drug therapy* / Q000276:immunology; D012795:Sialoglycoproteins / Q000627:therapeutic use*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D015703:Antigens, CD; C507763:IL1RN protein, human; C507764:Il1rn protein, mouse; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1; D018124:Receptors, Tumor Necrosis Factor; D047888:Receptors, Tumor Necrosis Factor, Type I; D012795:Sialoglycoproteins; D014409:Tumor Necrosis Factor-alpha